Interview: CellCentric Prostate Cancer Drug Promises Much
Executive Summary
The Cambridge-based company's CEO Will West tells Scrip that CCS1477 has shown a lot of potential for patients with late-stage prostate cancer who are resistant to second-line anti-androgen drugs like Zytiga and Xtandi and the $26m it has just raised will help fund development of the epigenetic therapy up to Phase IIb.
You may also be interested in...
Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks
Private Company Edition: Celgene's former top deal-maker George Golumbeski is now a life science business consultant and venture partner at ARCH. Also, a VC investment surge portends another big year for biopharma, including $85m for Ansun and $66m for FogPharma.
Takeda licenses epigenetic programme from CellCentric
Takeda has licensed an epigenetic programme from UK firm CellCentric with a primary focus on cancer. The deal, which includes an upfront payment, preclinical and clinical milestones, and royalties on any future products, could be worth more than $200 million to CellCentric over the course of the agreement.
Doubts Over DBV's Future As US FDA Rejects Peanut Allergy Patch
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.
Need a specific report? 1000+ reports available
Buy Reports